Designing and in-vitro characterization of micelle forming amphiphilic PEGylated rapamycin nanocarriers for the treatment of gastric cancer

Current Drug Delivery

Volumn 11, Issue 5, 2014, Pages 613-620

  Kumar, Palanirajan Vijayaraj ^a   Lokesh, Bontha Venkata Subrahmanya ^a  

^a UCSI UNIVERSITY   (Malaysia)

Author keywords

CRL 1658 NIH 3T3 mouse embryonic fibroblast cell lines ; Human gastric adenocarcinoma cell line (AGS, CRL 1739); Micelles; PEGylation; Rapamycin; Zeta potential

Indexed keywords

AMPHOPHILE; NANOCARRIER; RAPAMYCIN; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; NANOPARTICLE; SURFACTANT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; FIBROBLAST CULTURE; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC50; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MICELLIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHOTODYNAMICS; PHOTOSTABILITY; PROTON NUCLEAR MAGNETIC RESONANCE; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURFACE CHARGE; ZETA POTENTIAL; 3T3 CELL LINE; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; MICELLE; PATHOLOGY; STOMACH NEOPLASMS; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; SYNTHESIS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICELLES; NANOPARTICLES; NIH 3T3 CELLS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SIROLIMUS; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS;

EID: 84911466464     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720181105140922124759     Document Type: Article

References (57)

1. Sehgal, S. N.; Baker, H.; Vezina, C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot., 1975, 28 (10), 727-732.
2. Calne, R. Y.; Collier, D. S.; Lim, S.; Pollard, S. G.; Samaan, A.; White, D. J.; Thiru, S. Rapamycin for immunosuppression in organ allografting. Lancet, 1989, 2 (8656), 227.
3. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hsueh, T.; Chen, Y.; Wang, W.; Youngkin, D.; Liau, L.; Martin, N.; Becker, D.; Bergsneider, M.; Lai, A.; Green, R.; Oglesby, T.; Koleto, M.; Trent, J.; Horvath, S.; Mischel, P. S.; Mellinghoff, I. K.; Sawyers, C. L. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoSMed., 2008, 5 (1), e8.
4. Tai, W.; Chen, Z.; Barve, A.; Peng, Z.; Cheng, K. A novel rapamy-cin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm. Res., 2013, 31(3), 706-719.
5. Paine, M. F.; Leung, L. Y.; Watkins, P. B. New insights into drug absorption: studies with sirolimus. Ther. Drug Monit., 2004, 26 (5), 463-467.
6. Parhi, P.; Mohanty, C.; Sahoo, S. K. Enhanced cellular uptake and in vivo pharmacokinetics of rapamycin-loaded cubic phase nanoparticles for cancer therapy. Acta Biomater., 2011, 7 (10), 3656-3669.
7. Oyler, A. R.; Segmuller, B. E.; Sun, Y.; Polshyna, A.; Dunphy, R.; Armstrong, B. L.; Achord, P.; Maryanoff, C. A.; Alquier, L.; Il'ichev, Y. V. Forced degradation studies of rapamycin: identification of autoxidation products. J. Pharm. Biomed. Anal., 2012, 59, 194-200.
8. Benjamin, D.; Colombi, M.; Moroni, C.; Hall, M. N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov., 2011, 10 (11), 868-880.
9. Mathew, T. H.; Van Buren, C.; Kahan, B. D.; Butt, K.; Hariharan, S.; Zimmerman, J. J. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J. Clin. Oncol., 2006, 46 (1), 76-87.
10. Yanez, J. A.; Forrest, M. L.; Ohgami, Y.; Kwon, G. S.; Davies, N. M. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Che-mother. Pharmacol., 2008, 61 (1), 133-144.
11. Chen, H. H.; Mekkaoui, C.; Cho, H.; Ngoy, S.; Marinelli, B.; Waterman, P.; Nahrendorf, M.; Liao, R.; Josephson, L.; Sosnovik, D. E. Fluorescence tomography of rapamycin-induced autophagy and cardioprotection in vivo. Circ. Cardiovasc. Imaging, 2013, 6 (3), 441-447.
12. Liu, Q.; Zhang, J.; Sun, W.; Xie, Q. R.; Xia, W.; Gu, H. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int. J. Nanomed., 2012, 7, 999-1013.
13. Oliveira, R. R.; Ferreira, F. S.; Cintra, E. R.; Branquinho, L. C.; Ba-kuzis, A. F.; Lima, E. M. Magnetic nanoparticles and rapamycin encapsulated into polymeric nanocarriers. J. Biomed. Nanotechnol., 2011, 8 (2), 193-201.
14. Woo, H. N.; Chung, H. K.; Ju, E. J.; Jung, J.; Kang, H. W.; Lee, S. W.; Seo, M. H.; Lee, J. S.; Park, H. J.; Song, S. Y.; Jeong, S. Y.; Choi, E. K. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int. J. Nanomed., 2012, 7, 2197-2208.
15. Zago, A. C.; Raudales, J. C.; Attizzani, G.; Matte, B. S.; Yamamoto, G. I.; Balvedi, J. A.; Nascimento, L.; Kosachenco, B. G.; Centeno, P. R.; Zago, A. J. Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. Catheter. Cardiovasc. Interv., 2013, 81 (2), E124-E129.
16. Haeri, A.; Sadeghian, S.; Rabbani, S.; Anvari, M. S.; Boroumand, M. A.; Dadashzadeh, S. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis. Int. J. Pharm., 2011, 414 (1-2), 16-27.
17. Rouf, M. A.; Vural, I.; Renoir, J. M.; Hincal, A. A. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J. Liposome Res., 2009, 19 (4), 322-331.
18. Zhang, W.; Sun, Y.; Li, Y.; Shen, R.; Ni, H.; Hu, D. Preparation and influencing factors of sirolimus liposome by supercritical fluid. Artif. Cells Blood Substit. Immobil. Biotechnol., 2012, 40 (1-2), 62-65.
19. Hu, X.; Lin, C.; Chen, D.; Zhang, J.; Liu, Z.; Wu, W.; Song, H. Sirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluation. Int. J. Pharm., 2012, 438 (1-2), 123-133.
20. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics, CA Cancer. J. Clin., 2011, 61 (2), 69-90.
21. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, DM.; Forman, D.; Bray, F. GLO-BOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. http://globocan. iarc. fr/Pages/references. aspx(Accessed March 3, 2014).
22. World Health Organization. http://www. who. int/mediacentre/ factsheets/fs297/en/(Accessed March 3, 2014).
23. Dicken, B. J.; Bigam, D. L.; Cass, C.; Mackey, J. R.; Joy, A. A.; Hamilton, S. M. Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg., 2005, 241 (1), 27-39.
24. American Cancer Society. http://www. cancer. org/cancer/ stomachcancer/detailedguide/stomach-cancer-survival-rates (Accessed March 3, 2014).
25. Blanco, E.; Kessinger, C. W.; Sumer, B. D.; Gao, J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med., 2009, 234 (2), 123-131.
26. S, Kataoka, K. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano., 2012, 6 (6), 5174-5189.
27. Ko, J.; Park, K.; Kim, Y. S.; Kim, M. S.; Han, J. K.; Kim, K.; Park, R. W.; Kim, I. S.; Song, H. K.; Lee, D. S.; Kwon, I. C. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. J. Control Release, 2007, 123 (2), 109-115.
28. Min, K. H.; Kim, J. H.; Bae, S. M.; Shin, H.; Kim, M. S.; Park, S.; Lee, H.; Park, R. W.; Kim, I. S.; Kim, K.; Kwon, I. C.; Jeong, S. Y.; Lee, D. S. Tumoral acidic pH-responsive MPEG-poly(beta-amino ester) polymeric micelles for cancer targeting therapy. J. Control Release, 2010, 144 (2), 259-266.
29. Sezgin, Z.; Yuksel, N.; Baykara, T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm., 2007, 332 (1-2), 161-167.
30. Ricciutelli, M.; Di Martino, P.; Barboni, L.; Martelli, S. Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J. Pharm. Biomed. Anal., 2006, 41 (3), 1070-1074.
31. Tekade, R. K.; Kumar, P. V.; Jain, N. K. Dendrimers in oncology: an expanding horizon. Chem. Rev., 2009, 109 (1), 49-87.
32. Zhu, T. M. N. Y.; Fawzi, M. M. N. J. Water soluble rapamycin esters. U. S. Patent 2002/0055518 A1, May 9, 2002.
33. Joralemon, M. J.; McRae, S.; Emrick, T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chemical Commun, 2010, 46 (9), 1377-1393.
34. Gajbhiye, V.; Vijayaraj Kumar, P.; Tekade, R. K.; Jain, N. K. PE-Gylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur. J. Med. Chem., 2009, 44 (3), 1155-1166.
35. Kumar, P. V.; Agashe, H.; Dutta, T.; Jain, N. K. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr. Drug Delivery, 2007, 4 (1), 11-19.
36. Song, Q.; Wang, X.; Hu, Q.; Huang, M.; Yao, L.; Qi, H.; Qiu, Y.; Jiang, X.; Chen, J.; Chen, H.; Gao, X. Cellular internalization pathway and transcellular transport of pegylated polyester nanoparticles in Caco-2 cells. Int. J. Pharm., 2013, 445 (1-2), 58-68.
37. Etrych, T.; Kovář, L.; Strohalm, J.; Chytil, P.; Říhová, B.; Ulbrich, K. Biodegradable star HPMA polymer-drug conjugates: Biode-gradability, distribution and anti-tumor efficacy. J. Controlled Release, 2011, 154 (3), 241-248.
38. Gu, J. R. E. N. J.; Ruppen, M. G. N. Y.; Zhu, T. M. N. Y.; Fawzi, M. M. N. J. Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants. U. S. Patent 7605257, Octobar 20, 2009.
39. Kumar, P. V.; Choudary, R. K.; Rakesh Narne, R. Efavirenz loaded novel citric acid dendritic architecture for increased solubility and sustained delivery. J. Pharm. Drug Delivery Res., 2012, 1 (1), 5. http://www. scitechnol. com/2325-9604/2325-9604-1-103. php? article_id=249.
40. Yokoyama, M.; Miyauchi, M.; Yamada, N.; Okano, T.; Sakurai, Y.; Kataoka, K.; Inoue, S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res., 1990, 50 (6), 1693-700.
41. Torchilin, V. P. Structure and design of polymeric surfactant-based drug delivery systems. J. Controlled Release, 2001, 73 (2-3), 137-172.
42. Jones, M.-C.; Leroux, J.-C. Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharma. Biopharma., 1999, 48 (2), 101-111.
43. Yokoyama, M. Clinical applications of polymeric micelle carrier systems in chemotherapy and image diagnosis of solid tumors. J. Exp. Clin. Med., 2011, 3 (4), 151-158.
44. Blanazs, A.; Armes, S. P.; Ryan, A. J. Self-Assembled block copolymer aggregates: from micelles to vesicles and their biological applications. Macromol. Rapid Commun., 2009, 30 (4-5), 267-277.
45. Erel, I.; Zhu, Z.; Sukhishvili, S.; Patyukova, E.; Potemkin, I.; Kramarenko, E. Two types of block copolymer micelles with ion-containing cores. Macromol. Rapid Commun., 2010, 31 (5), 490-495.
46. Gohy, J. F.; Lohmeijer, B. G.; Alexeev, A.; Wang, X. S.; Manners, I.; Winnik, M. A.; Schubert, U. S. Cylindrical micelles from the aqueous self-assembly of an amphiphilic poly(ethylene oxide)-b-poly(ferrocenylsilane) (PEO-b-PFS) block copolymer with a met-allo-supramolecular linker at the block junction. Chemistry, 2004, 10 (17), 4315-4323.
47. Zhu, J.; Hayward, R. C. Spontaneous generation of amphiphilic block copolymer micelles with multiple morphologies through interfacial Instabilities. JACS., 2008, 130 (23), 7496-7502.
48. Rafi, M.; Cabral, H.; Kano, M. R.; Mi, P.; Iwata, C.; Yashiro, M.; Hirakawa, K.; Miyazono, K.; Nishiyama, N.; Kataoka, K. Polymeric micelles incorporating (1, 2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J. Controlled Release, 2012, 159 (2), 189-196.
49. Wisniewska, M. The temperature effect on electrokinetic properties of the silica-polyvinyl alcohol (PVA) system. Colloid Polymer Sci., 2011, 289 (3), 341-344.
50. Xiao, K.; Li, Y.; Luo, J.; Lee, J. S.; Xiao, W.; Gonik, A. M.; Agar-wal, R. G.; Lam, K. S. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials, 2011, 32 (13), 3435-3446.
51. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine, 2011, 6 (4), 715-728.
52. Weibel, H.; Nielsen, L. S.; Larsen, C.; Bundgaard, H. Macromo-lecular prodrugs. IXX. Kinetics of hydrolysis of benzyl dextran carbonate ester conjugates in aqueous buffer solutions and human plasma. Acta. Pharm. Nord., 1991, 3 (3), 159-162.
53. Xu, D. Z.; Geng, Q. R.; Tian, Y.; Cai, M. Y.; Fang, X. J.; Zhan, Y. Q.; Zhou, Z. W.; Li, W.; Chen, Y. B.; Sun, X. W.; Guan, Y. X.; Li, Y. F.; Lin, T. Y. Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer, 2010, 10, 536.
54. Sezgin, Z.; Yuksel, N.; Baykara, T. Investigation of pluronic and PEG-PE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int. J. Pharm., 2007, 332 (1-2), 161-167.
55. Nuttelman, C. R.; Mortisen, D. J.; Henry, S. M.; Anseth, K. S. Attachment of fibronectin to poly(vinyl alcohol) hydrogels promotes NIH3T3 cell adhesion, proliferation, and migration. J. Biomed. Mater. Res., 2001, 57 (2), 217-223.
56. Namdeo, A. B. B.; Subramanian, N. B.; Balaram Bhowmick, S. B. Pharmaceutical Compositions. U. S. Patent 20080262078 A1, October 23, 2008.
57. Kim, T. Y.; Kim, D. W.; Chung, J. Y.; Shin, S. G.; Kim, S. C.; Heo, D. S.; Kim, N. K.; Bang, Y. J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated pa-clitaxel, in patients with advanced malignancies. Clin. Cancer Rer., 2004, 10 (11), 3708-3716.